Skip to main content

Table 7 Study C: PPIV-1 vaccine study. Percent of anti-PPIV-1 antibody positive pigs at vaccination or exposure (0 DPV) and 11, 18, 24, 31, 38, 43, and 48 DPV. A total of 50 piglets were included in this study. Treatment groups included live exposure/challenged (LE/C), non-vaccinated/challenged (NV/C), non-vaccinated/non-challenged (NV/NC), RNA particle vaccinated/challenged (RP/C), and adjuvanted RNA particle/challenged (RPAdj/C). Assay thresholds were determined by ROC analysis at a specificity of 99% while maximizing sensitivity. Values within an experimental group by DPV with different superscripts were significantly different at p ≤ 0.05 by McNemar’s test. Asterisks indicate significant Cochran’s Q test by DPV but nonsignificant individual McNemar’s pairwise testing

From: Detection of porcine parainfluenza virus type-1 antibody in swine serum using whole-virus ELISA, indirect fluorescence antibody and virus neutralizing assays

  

Days Post Vaccination (DPV)

Treatment

Assay

0

11

18

24

31

38

43

48

LE/C

wv-ELISAA

0 (0/10)1

30 (3/10)b

100 (10/10)*

100 (10/10)*

100 (10/10)

100 (10/10)*

100 (10/10)

100 (10/10)*

IFAB

0 (0/10)

10 (1/10)b

70 (7/10)*

60 (6/10)*

100 (10/10)

50 (5/10)*

60 (6/10)

100 (10/10)*

SVNC

0 (0/10)

100 (10/10)a

100 (10/10)*

100 (10/10)*

100 (10/10)

90 (9/10)*

90 (9/10)

70 (7/10)*

NV/C

wv-ELISAA

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

10 (1/10)

0 (0/10)

0 (0/10)

IFAB

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

SVNC

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

NV/NC

wv-ELISAA

0 (0/10)

20 (2/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

IFAB

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

SVNC

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

0 (0/10)

RP/C

wv-ELISAA

0 (0/10)

0 (0/10)*

20 (2/10)ab

20 (2/10)*

100 (10/10)

100 (10/10)

100 (10/10)

100 (10/10)

IFAB

0 (0/10)

0 (0/10)*

0 (0/10)b

10 (1/10)*

100 (10/10)

100 (10/10)

100 (10/10)

100 (10/10)

SVNC

0 (0/10)

50 (5/10)*

80 (8/10)a

50 (5/10)*

100 (10/10)

100 (9/9)

100 (10/10)

100 (10/10)

RPAdj/C

wv-ELISAA

0 (0/10)

0 (0/10)*

70 (7/10)*

60 (6/10)*

100 (10/10)

100 (10/10)

100 (10/10)

100 (10/10)

IFAB

0 (0/10)

0 (0/10)*

50 (5/10)*

100 (10/10)*

100 (10/10)

100 (10/10)

100 (10/10)

100 (10/10)

SVNC

0 (0/10)

60 (6/10)*

100 (10/10)*

100 (10/10)*

100 (10/10)

100 (10/10)

100 (10/10)

100 (10/10)

  1. ASamples with a sample/positive (S/P) ratio greater than 0.14 were considered positive. Samples with a S/P ratio less than 0.14 were considered negative
  2. BSamples with an IFA reciprocal titer greater than or equal to 40 were considered positive. Samples with an IFA titer less than 40 were considered negative
  3. CSamples with a VN titer greater than or equal to 20 were considered positive. Samples with a VN titer less than 20 were considered negative
  4. 1Antibody positive/treatment group size; wv-ELISA Whole virus ELISA, IFA Indirect fluorescence antibody, SVN Serum virus neutralization